Search
Mizolastine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175130Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeMeclizine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175079Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeChlorpromazine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175151Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeTripelennamine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175081Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeEmedastine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175087Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeAlcaftadine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175095Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeAntazoline H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175096Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeBuclizine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175104Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeBromodiphenhydramine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175107Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeRupatadine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175117Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha type